Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge

Participants who had received placebo in a previous phase of this trial were offered the mRNA-1273 vaccine in the open-label phase. The incidence of Covid-19 in this group was lower than that in the group of participants who had been vaccinated earlier, reflecting a modest waning of vaccine efficacy...

Full description

Saved in:
Bibliographic Details
Published in:New England Journal of Medicine 2021-12
Main Authors: Baden, Lindsey R, El Sahly, Hana M, Essink, Brandon, Follmann, Dean, Neuzil, Kathleen M, August, Allison, Clouting, Heather, tier, Gabrielle, Deng, Weiping, Han, Shu, Zhao, Xiaoping, Leav, Brett, Talarico, Carla, Girard, Bethany, Paila, Yamuna D, Tomassini, Joanne E, Schödel, Florian, Pajon, Rolando, Zhou, Honghong, Das, Rituparna, Miller, Jacqueline
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Participants who had received placebo in a previous phase of this trial were offered the mRNA-1273 vaccine in the open-label phase. The incidence of Covid-19 in this group was lower than that in the group of participants who had been vaccinated earlier, reflecting a modest waning of vaccine efficacy over time.
DOI:10.1056/NEJMc2115597